309
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Characterization of Severe Uncontrolled Asthma in Japan: Analysis of Baseline Data from the PROSPECT Study

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, , , ORCID Icon, & show all
Pages 597-609 | Received 27 Feb 2023, Accepted 07 May 2023, Published online: 02 Jun 2023

References

  • Nakamura Y, Tamaoki J, Nagase H, et al. Japanese guidelines for adult asthma 2020. Allergol Int. 2020;69:519–548. doi:10.1016/j.alit.2020.08.001
  • Nagase H, Adachi M, Matsunaga K, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2020;69:53–60. doi:10.1016/j.alit.2019.06.003
  • Sato K, Ohno T, Ishii T, Ito C, Kaise T. The prevalence, characteristics, and patient burden of severe asthma determined by using a Japan health care claims database. Clin Ther. 2019;41:2239–2251. doi:10.1016/j.clinthera.2019.08.015
  • Inoue H, Kozawa M, Milligan KL, Funakubo M, Igarashi A, Loefroth E. A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan. NPJ Prim Care Respir Med. 2019;29:13. doi:10.1038/s41533-019-0128-8
  • Calhoun WJ, Haselkorn T, Miller DP, Omachi TA. Asthma exacerbations and lung function in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2015;136:1125–1127. doi:10.1016/j.jaci.2015.05.014
  • Matsunaga K, Adachi M, Nagase H, Okoba T, Hayashi N, Tohda Y. Association of low-dosage systemic corticosteroid use with disease burden in asthma. NPJ Prim Care Respir Med. 2020;30:35. doi:10.1038/s41533-020-00192-x
  • McGeachie MJ, Yates KP, Zhou X, et al. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med. 2016;374:1842–1852. doi:10.1056/NEJMoa1513737
  • Menzies-Gow A, Szefler SJ, Busse WW. The relationship of asthma biologics to remission for asthma. J Allergy Clin Immunol Pract. 2021;9:1090–1098. doi:10.1016/j.jaip.2020.10.035
  • O’Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P. Asthma progression and mortality: the role of inhaled corticosteroids. Eur Respir J. 2019;54:1900491. doi:10.1183/13993003.00491-2019
  • Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127. doi:10.1016/S0140-6736(16)31324-1
  • FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141. doi:10.1016/S0140-6736(16)31322-8
  • Haldar P, Brightling C, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–984. doi:10.1056/NEJMoa0808991
  • Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573–582. doi:10.7326/0003-4819-154-9-201105030-00002
  • Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–1207. doi:10.1056/NEJMoa1403290
  • Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659. doi:10.1016/S0140-6736(12)60988-X
  • Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31–44. doi:10.1016/S0140-6736(16)30307-5
  • Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197. doi:10.1056/NEJMoa1403291
  • Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–2458. doi:10.1056/NEJMoa1703501
  • Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475–2485. doi:10.1056/NEJMoa1804093
  • Matsusaka M, Fukunaga K, Kabata H, Izuhara K, Asano K, Betsuyaku T. Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract. 2018;6:274–6.e2. doi:10.1016/j.jaip.2017.06.015
  • Kimura H, Makita H, Taniguchi N, et al. Determination of the cutoff values of Th2 markers for the prediction of future exacerbation in severe asthma: an analysis from the Hokkaido severe asthma cohort study. Allergol Int. 2021;70:68–73. doi:10.1016/j.alit.2020.09.001
  • Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373. doi:10.1183/09031936.00202013
  • Tanosaki T, Kabata H, Matsusaka M, et al. Clinical characteristics of patients with not well-controlled severe asthma in Japan: analysis of the Keio Severe Asthma Research Program in Japanese population (KEIO-SARP) registry. Allergol Int. 2021;70:61–67. doi:10.1016/j.alit.2020.06.002
  • Kimura H, Konno S, Nakamaru Y, et al. Sinus computed tomographic findings in adult smokers and nonsmokers with asthma. Analysis of clinical indices and biomarkers. Ann Am Thorac Soc. 2017;14:332–341. doi:10.1513/AnnalsATS.201606-463OC
  • Ministry of Health, Labour and Welfare, Japan. 高齢者医療制度 [Medical System for the Elderly]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryouhoken/koukikourei/index.html. Accessed September 30, 2022. Japanese.
  • Bjornson BH, Harvey JM, Rose L. Differential effect of hydrocortisone on eosinophil and neutrophil proliferation. J Clin Invest. 1985;76:924–929. doi:10.1172/JCI112091
  • Tamada T, Fukui K, Makita N, et al. 重症喘息患者における生物学的製剤の推奨プロセスに関するインターネット調査 (KOFU study 第2報) [An internet survey on the recommendation process of biologics in severe asthma patients]. Ther Res. 2021;42:857–866. Japanese.
  • Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716–725. doi:10.1038/nm.2678
  • Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386:157–171. doi:10.1056/NEJMra2032506
  • Jackson DJ, Busby J, Pfeffer PE, et al. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. Thorax. 2021;76:220–227. doi:10.1136/thoraxjnl-2020-215168
  • Horiguchi T, Kuwabara K, Kato R. 難治性喘息診断と治療の手引き2019 (成人) [The JRS guidelines 2019 for the management of refractory asthma]. Arerugi. 2021;70:10–14. Japanese. doi:10.15036/arerugi.70.10